Additional Information

Description

Mounjaro (tirzepatide) 2.5 mg/0.5 mL is a once-weekly injectable medication used for the treatment of type 2 diabetes mellitus. It is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. By mimicking the effects of these incretin hormones, it enhances insulin secretion, suppresses glucagon levels, and slows gastric emptying, leading to improved glycemic control.

The prefilled pen delivers a fixed dose of 2.5 mg tirzepatide in 0.5 mL solution. It is designed for patient self-administration and features an automatic needle retraction system to enhance safety. Injection sites include the abdomen, thigh, or upper arm, with rotation recommended to avoid irritation. The medication should not be used in patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Common side effects include nausea, vomiting, diarrhea, decreased appetite, and abdominal pain. Severe adverse reactions may include pancreatitis, hypoglycemia when combined with insulin or sulfonylureas, and hypersensitivity reactions. Regular monitoring of blood glucose and kidney function is recommended during treatment.